ABSTRACT
Background: Severe Acute Respiratory Syndrome Corona Virus 2(SARS?CoV?2) is the novel corona virus first detected in Wuhan in 2019. nCOV belongs to the ?-corona virus cluster. As the third most highly pathogenic corona virus, the clinical presentations of 2019-nCoV infection resemble those of the other two corona viruses, Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV) and Middle East Respiratory Syndrome Corona Virus (MERS-CoV). The abnormalities in the laboratory indices particularly the Blood Biochemical parameters may be associated with the severity of multiple organ dysfunction seen in COVID-19. The aim of the present project was to analyze the laboratory diagnostic profile of sars?cov?2 (covid?19) patients & to study the associated factors.Methods: The present hospital � based cross sectional study was conducted on all the patients who had tested positive for COVID & were admitted in Rajindra Hospital, Patiala in the time period of the July 2020 to December 2020, during the declared Corona Virus Pandemic. All the Biochemical Parameters were estimated on the automatic Analysers.Results: The results of the present study show abnormalities in the Renal Function Tests, Liver Function Tests, Blood sugar levels and Serum Electrolytes. Blood sugar levels and Renal function tests are significantly deranged in the patients of Covid 19 having co-morbidities like Diabetes Mellitus, Hypertension, CAD, CKD, Hypothyroidism etc: Conclusions:Biochemical Laboratory parameters
ABSTRACT
Background: Discovery of novel biomarkers of prognosis and drug response remains an elusive, yet critical goal. Thus, accurate and rapid screening of an array of pertinent mutations/SNPs is an essential step in cancer management. Methods: Using a high-throughput multiplex PCR microarray technique, we simultaneously screened the mutational status/SNP of 32 hotspots in multiple genes for metastatic colorectal cancer (mCRC) from 126 formalin fixed paraffin embedded samples from 78 patients. The efficacy of the technology was validated by cross-comparison with conventional Sanger sequencing and pyrosequencing. The clinical outcome was corroborated to the mutational status to determine prognostic and predictive significance of the 32 loci. Results: In a statistically robust multivariate model, patients with the TT genotype of the MGMT gene (rs1625649) enjoyed a significantly longer survival (61.8 months) when compared to those with GG or heterozygous GT genotype (29.3 months) [HR 0.30; 95% CI: 0.10-0.89, P= 0.03], with a 70% reduced risk of death from mCRC. Conclusion: The rs1625649 SNP within MGMT is a novel and potentially valuable prognostic biomarker for mCRC patients.
ABSTRACT
Cu (II) and Ni (II) complexes of general composition [ML2]X2 (M = Cu(II), Ni(II); X = Cl-, NO3 -) were synthesized by the condensation of metal salts with semicarbazone / thiosemicarbazone derived from pdimethylaminobanzaldehyde. The metal complexes were characterized by elemental analysis, molar conductance, magnetic susceptibility measurements, IR and atomic absorption spectral studies. On the basis of electronic and infrared spectral studies, the metal complexes were found to have tetrahedral geometry. The Schiff bases and their metal complexes were tested for their antibacterial and antioxidant activities.
Subject(s)
Anastomosis, Surgical , Aortic Aneurysm/complications , Aortic Valve Insufficiency/complications , Aortic Valve Stenosis/complications , Blood Vessel Prosthesis Implantation , Coronary Angiography , Coronary Vessel Anomalies/complications , Echocardiography, Transesophageal , Humans , Male , Middle Aged , Tomography, X-Ray ComputedABSTRACT
Sixty six patients undergoing elective valve surgery were randomized to receive rocuronium bromide 0.6 mg/Kg (Group R, n=22), pancuronium bromide 0.1 mg/Kg (Group P, n= 22) and vecuronium bromide 0.1 mg/Kg (Group V, n=22), Measurements of heart rate and arterial pressure (systolic, diastolic and mean) were noted at the following stages: 1) baseline when haemodynamics were stable for 2 minutes after induction of anaesthesia (2) one, (3) three, (4) five minutes after administration of muscle relaxants, (5) One, (6) three, and (7) five minutes after intubation. In group R, the heart rate decreased 5 min after injection of muscle relaxant from 93.9 +/- 21.3 to 82.4 +/- 20.7 beats/min (p<0.001). However, it increased to 128.3 +/- 25.8 beats/min (p<0.001) following intubation and returned to baseline at 5 min after intubation. In group P, heart rate increased from 98.8 +/- 32.6 to 109.6 +/- 32.7 beats/min (p<0.001), 1 min after injection of pancuronium and this increase persisted throughout the study period. In group V, heart rate decreased from 99.9 +/- 22.3 to 83.8 +/-19.6 beats/min (p<0.001) at 5 min after injection of the drug. It increased to 118.6 +/- 22.4 beats/min (p<0.001), 1 min after intubation and returned to baseline at 5 min after intubation. The decrease in heart rate in group R and V was accompanied by a significant decrease in systolic, diastolic and mean arterial pressure. In group P, only the systolic pressure decreased significantly at 5 min after injection of the drug. Intubation was accompanied by a significant increased in systolic, diastolic and mean arterial pressure in all the groups. Excellent intubation conditions (intubation score 3-4) were observed with all the three drugs, however, there were number of patients in group P who showed diaphragmatic movement during intubation. Onset of action of muscle relaxant, was fastest with rocuronium (group R=132.7 +/- 0.3 sec, P=182.6 +/- 68.5 sec, V= 144.8 +/- 46.1 sec, Group P vs Group R). To conclude, pancuronium causes significant increase in heart rate and should be preferred in patients with regurgitant lesions having slower baseline heart rate. Vecuronium and rocuronium decrease the heart rate and should be preferred in patient with faster baseline heart rate. In terms of intubating conditions rocuronium and vecuronium provide best conditions, but onset is faster with rocuronium.